StockNews.com Lowers MiMedx Group (NASDAQ:MDXG) to Buy

StockNews.com lowered shares of MiMedx Group (NASDAQ:MDXG) from a strong-buy rating to a buy rating in a research note issued to investors on Tuesday morning.

MDXG has been the topic of several other research reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $11.00 price target on shares of MiMedx Group in a research note on Thursday, August 1st. Craig Hallum dropped their price target on MiMedx Group from $14.00 to $12.00 and set a “buy” rating on the stock in a research note on Thursday, August 1st. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $12.00.

MiMedx Group Stock Performance

MDXG opened at $5.83 on Tuesday. The business’s 50-day moving average price is $6.16 and its two-hundred day moving average price is $6.73. MiMedx Group has a 1 year low of $5.47 and a 1 year high of $9.27. The company has a market capitalization of $860.53 million, a price-to-earnings ratio of 13.25 and a beta of 1.97. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.85 and a quick ratio of 3.22.

MiMedx Group (NASDAQ:MDXG) last released its quarterly earnings results on Wednesday, July 31st. The company reported $0.08 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.08. MiMedx Group had a return on equity of 34.24% and a net margin of 23.63%. The firm had revenue of $87.21 million for the quarter, compared to the consensus estimate of $88.44 million. Equities analysts expect that MiMedx Group will post 0.26 EPS for the current fiscal year.

Institutional Trading of MiMedx Group

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. ProShare Advisors LLC increased its position in shares of MiMedx Group by 8.5% in the first quarter. ProShare Advisors LLC now owns 20,735 shares of the company’s stock valued at $160,000 after acquiring an additional 1,631 shares during the last quarter. Hsbc Holdings PLC increased its position in MiMedx Group by 7.3% during the second quarter. Hsbc Holdings PLC now owns 34,343 shares of the company’s stock worth $233,000 after buying an additional 2,329 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in MiMedx Group by 7.6% during the second quarter. The Manufacturers Life Insurance Company now owns 45,623 shares of the company’s stock worth $316,000 after buying an additional 3,222 shares during the last quarter. Marshall Wace LLP increased its position in MiMedx Group by 1.1% during the second quarter. Marshall Wace LLP now owns 298,818 shares of the company’s stock worth $2,071,000 after buying an additional 3,223 shares during the last quarter. Finally, Headlands Technologies LLC acquired a new position in MiMedx Group during the first quarter worth approximately $27,000. Institutional investors and hedge funds own 79.15% of the company’s stock.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.